Wockhardt's Novel Antibiotic Zaynich Receives Approval from CDSCO Expert Panel

Wockhardt Edges Closer to Commercializing Novel Antibiotic Zaynich for Treating Hard-to-Treat Gram-Negative Infections

Wockhardt has inched closer to commercializing its novel antibiotic Zaynich for treating hard-to-treat gram-negative infections, after India's drug regulator's expert panel gave its nod. The Central Drugs Standard Control Organisation (CDSCO) has issued a favourable recommendation for Zaynich, a combination of zidebactam and cefepime, paving the way for a final decision by the Drugs Controller General of India (DCGI). Such recommendations are typically a precursor to approval by DCGI, though they are not binding.

Zaynich targets multi-drug resistant and extensively drug-resistant gram-negative pathogens, a growing global health threat as resistance to existing antibiotics accelerates. Zidebactam acts as a so-called beta-lactam enhancer, boosting the activity of cefepime through a novel mechanism distinct from traditional beta-lactamase inhibitors. The drug has been more than 15 years in development and has been evaluated in a broad clinical programme, including nine Phase 1 studies, a Phase 2 trial in meropenem-resistant infections, and a global Phase 3 study comparing it with meropenem, a widely used last-line antibiotic.

Phase 3 Trial Shows Superiority of Zaynich Over Meropenem

Read also: Pfizer Introduces Novel Myeloma Treatment in India for Patients with Limited Therapeutic Options

In the Phase 3 trial, conducted across 64 sites in the US, Europe, Latin America, China, and India, Zaynich showed superiority over meropenem on a combined clinical and microbiological cure endpoint in complicated urinary tract infections and acute pyelonephritis. Data from compassionate-use cases in India and overseas further supported its use in settings with limited treatment options.

The regulatory progress is strategically significant for Wockhardt, which has been working to rebuild after years of stress in its generics business. Unlike commodity generics, a successful launch of Zaynich would give the company a patented, differentiated asset with pricing power, mainly in hospital-driven tertiary care settings.

Global Opportunity for Wockhardt

India, however, is only part of the opportunity. Wockhardt has already submitted approval applications in the US and European Union, both of which are in advanced stages of review. Antibiotics addressing resistant infections have increasingly drawn regulatory attention in Western markets, where pipelines remain thin.

Read also: Lilly Launches Novel Alzheimer's Treatment Lormalzi in India at Rs 91,688 per Vial

The next key trigger is a final decision from India's drug controller. Beyond that, investor focus will shift to global approval timelines and how aggressively Wockhardt monetises one of its longest-running innovation bets.